| Autor: |
Kyriazopoulou, E. Panagopoulos, P. Metallidis, S. Dalekos, G.N. Poulakou, G. Gatselis, N. Karakike, E. Saridaki, M. Loli, G. Stefos, A. Prasianaki, D. Georgiadou, S. Tsachouridou, O. Petrakis, V. Tsiakos, K. Kosmidou, M. Lygoura, V. Dareioti, M. Milionis, H. Papanikolaou, I.C. Akinosoglou, K. Myrodia, D.-M. Gravvani, A. Stamou, A. Gkavogianni, T. Katrini, K. Marantos, T. Trontzas, I.P. Syrigos, K. Chatzis, L. Chatzis, S. Vechlidis, N. Avgoustou, C. Chalvatzis, S. Kyprianou, M. van der Meer, J.W.M. Eugen-Olsen, J. Netea, M.G. Giamarellos-Bourboulis, E.J. |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Popis: |
Background It was studied if early suPAR-guided anakinra treatment can prevent severe respiratory failure (SRF) of COVID-19. Methods 130 patients with suPAR ≥6 ng/ml were assigned to subcutaneous anakinra 100mg once daily for 10 days. Primary outcome was SRF incidence by day 14 defined as any respiratory ratio below 150 mmHg necessitating mechanical or non-invasive ventilation. Main secondary outcomes were 30-day mortality and inflammatory mediators; 28-day WHO-CPS was explored. Propensity-matched standard-of care comparators were studied. Results 22.3% with anakinra treatment and 59.2% comparators (hazard ratio, 0.30; 95%CI, 0.20-0.46) progressed into SRF; 30-day mortality was 11.5% and 22.3% respectively (hazard ratio 0.49; 95% CI 0.25-0.97). Anakinra was associated with decrease in circulating interleukin (IL)-6, sCD163 and sIL2-R; IL-10/IL-6 ratio on day 7 was inversely associated with SOFA score; patients were allocated to less severe WHO-CPS strata. Conclusions Early suPAR-guided anakinra decreased SRF and restored the pro-/anti-inflammatory balance. Trial Registration: ClinicalTrials.gov, NCT04357366. © 2021, eLife Sciences Publications Ltd. All rights reserved. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
